Abstract 1487P
Background
Information and Communication Technology-based self-management support has been demonstrated to be effective in relieving symptoms for patients with advanced cancer. This study aimed to evaluate the effectiveness of a telemonitoring system for cancer pain relief in outpatients with advanced cancer in Japan.
Methods
The study was conducted between December 2019 and February 2023. This study included patients attending Tohoku University Hospital as outpatients, regularly taking opioids for cancer pain, with a mean pain NRS of ≥3 in 24 hours. Participants were randomized into intervention and control groups in a 1:1 ratio. The intervention group received telemonitoring care using the Cancer Pain Monitoring System (CAPAMOS). This comprises five components: symptom checks, medication checks, graphical records, pain booklet, and contact with a telenurse (chats, phones, and video phones). Alerts were sent to a telenurse when a patient’s symptoms worsened. The control group maintained a pain diary. An assessment of pain (NRS), quality of life (VAS), and opioid self-management scale (Opioid Self-Management Scale for Advanced Cancer Patients with Pain: OSSA) was conducted at baseline and after 2 and 4 weeks. Further, the Ethics Committee of Tohoku University Graduate School of Medicine reviewed the study (approval no. 2020-1-194).
Results
A total of 48 patients were enrolled in this study. There were no significant differences in baseline age (intervention 53.5 vs. control 57.0, p=0.68), severe pain (5.0 vs. 5.0, p=0.92), average pain (4.0 vs. 4.0, p=0.41), OSSA scores (135.0 vs. 130.0, p=0.06) and QOL (70.0 vs. 64.0, p=0.86) between groups. At 2 weeks post-intervention, no significant association was observed. At 1 month post-intervention, severe pain (5.0 vs. 5.5, p = 0.37), average pain (3.0, vs. 4.0, p = 0.41), OSSA scores (136.5 vs. 123.5, p=0.06), and QOL scores (57.5 vs. 50.0, p = 0.58) were not statistically significant. The scores for understanding pain characteristics in OSSA were significantly higher in the OSSA group than in the control group (10.0 vs. 8.0, p=0.04).
Conclusions
Telemonitoring support has led to educational advantages, such as improving patients’ understanding of opioid self-management and pain characteristics.
Clinical trial identification
UMIN000038334.
Editorial acknowledgement
Legal entity responsible for the study
Tohoku University Graduate School of Medicine.
Funding
JSPS KAKENHI.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10